July 13, 2026•Ilyssa Levins-Pimienta

Governance in Pharma: Why It Is More Than Compliance and the Foundation for Commercialization Readiness

What Is Governance of Scientific and Promotional Communications?

When most pharmaceutical organizations hear the word "governance," they think about compliance — Medical, Legal, and Regulatory (MLR) review, approval workflows, and the controls required to reduce regulatory risk. While compliance is an important outcome, governance serves a much broader purpose. It is the framework that ensures scientific, medical, promotional, investor, and corporate communications are accurate, consistent, substantiated, and traceable to approved evidence.

At its core, governance answers a simple question: can every claim, statement, or communication made by the organization be linked back to approved scientific evidence and communicated consistently wherever it appears?

Governance is not simply about controlling risk. It is about ensuring that scientific knowledge can be efficiently transformed into compliant, consistent, and scalable communications across the enterprise. Unfortunately, many organizations still manage this process manually.

The Four Problems With Manual Governance Processes

As communication volumes continue to increase, governance becomes increasingly difficult to manage through spreadsheets, shared drives, email chains, disconnected repositories, and manual review processes. These approaches may work when communication volume is low, but they rarely scale.

1. Scientific Evidence Becomes Difficult to Find

Most organizations have hundreds or thousands of publications, references, presentations, labels, congress materials, and approved communications. When approved claims and supporting evidence are scattered across repositories, teams spend significant time searching for information that already exists:

Medical Affairs teams struggle to locate references.
Commercial teams recreate previously approved messaging.
Agencies repeatedly validate the same claims.
Scientific knowledge becomes trapped inside documents instead of being available for reuse.

2. Messaging Becomes Inconsistent Across Channels

The same clinical data is often communicated differently by different teams:

Medical Affairs may describe outcomes one way.
Commercial teams may use different language.
Investor presentations may emphasize different findings.
Agency partners may develop alternative versions of approved messages.

Without a centralized governance framework, organizations risk creating inconsistent interpretations of the same scientific evidence. The issue is not always compliance — it is consistency.

3. Review Burden Continues to Increase

As communication volume grows, reviewers spend increasing amounts of time performing repetitive verification activities. Instead of focusing on strategic medical, legal, or regulatory assessment, reviewers often spend valuable time:

Verifying references
Confirming claim substantiation
Checking approved language
Resolving inconsistencies
Identifying unsupported statements

This creates bottlenecks that slow communication without necessarily improving quality.

Not sure how many review bottlenecks are slowing your MLR submissions right now? Take the free PreCheck Readiness Assessment to identify gaps before your next submission.

4. Commercialization Opportunities Are Delayed

The greatest cost of weak governance is often hidden. When new Phase 3 data is released, a publication becomes available, a congress presentation is delivered, or new evidence emerges, organizations need to rapidly communicate that information to healthcare professionals. Without effective governance, teams spend weeks locating evidence, rebuilding claims, validating references, and navigating review cycles.

Every day spent preparing communications is a day that important scientific information is not reaching physicians, patients, payers, and other stakeholders — and every delay reduces the opportunity to maximize the value of scientific investments and accelerate commercial impact.

Governance Is More Than Compliance

Many organizations evaluate governance solely through the lens of risk reduction. That perspective overlooks the much larger business value governance creates: it enables organizations to move scientific information from evidence to communication more efficiently.

Medical Affairs teams can respond more quickly to scientific inquiries because supporting evidence is easier to locate.
Commercial teams can develop materials with greater confidence because approved claims and references are readily accessible.
Agency partners can reuse validated scientific content rather than recreating it.
Reviewers can focus on strategic evaluation rather than repetitive fact-checking.

Most importantly, governance accelerates the dissemination of scientific information. Every day that a publication, congress presentation, scientific update, or clinical data release is delayed represents a missed opportunity to educate healthcare professionals, strengthen customer engagement, support prescribing decisions, and maximize the value of scientific investments.

Organizations that can efficiently review, approve, and distribute evidence-based communications are better positioned to translate new data into meaningful clinical and commercial impact. In this way, governance becomes much more than a compliance initiative — it becomes a competitive advantage.

How AI-Powered Governance Changes the Model

The emergence of generative AI has made governance more important than ever. Many organizations are exploring how AI can accelerate content creation, review preparation, scientific communications, and commercialization activities. However, AI can only be as reliable as the information it uses. If approved claims, references, and supporting evidence are scattered across disconnected documents and repositories, AI systems must attempt to determine which information is current, approved, and substantiated — and that creates risk.

A governance-driven approach changes the equation. Instead of relying on fragmented content, organizations can establish structured repositories of approved scientific knowledge that contain:

Approved claims
Supporting references
Source documentation
Scientific context
Audience-specific guidance
Regulatory considerations
Approved promotional language

These governance assets become the foundation for both human and AI-driven communications. Consider an organization preparing for the release of important Phase 3 clinical data. Without structured governance, teams often spend weeks identifying supporting evidence, rebuilding claims, validating references, and creating communications for multiple audiences. With governance already established, scientific knowledge can be rapidly reused across Medical Affairs, commercial, investor, training, and promotional communications while maintaining consistency and traceability.

AI can further accelerate this process by helping teams:

Identify approved claims
Verify references
Assess consistency
Evaluate materials before formal review

The result is not simply improved compliance — it is faster dissemination of scientific information, greater operational efficiency, and increased commercialization readiness.

Governance Is a Commercialization Readiness Strategy

The life sciences industry is entering an era where communication speed matters more than ever. Organizations must rapidly translate clinical evidence into:

Scientific exchange
Healthcare professional education
Promotional communications
Investor engagement
Digital content

Those that rely on fragmented governance processes will continue to experience delays, inefficiencies, and inconsistent messaging.

Those that establish governance as a strategic capability will be better positioned to scale communications, support AI initiatives, accelerate dissemination of scientific evidence, and maximize the value of their scientific investments. The purpose of governance is enabling organizations to consistently transform evidence into communication, communication into engagement, and engagement into clinical and commercial impact.

See where your organization stands today. Take the free PreCheck Readiness Assessment — get a clear picture of your content governance readiness before it reaches MLR review.

About SecureCHEK AI

SecureCHEK AI is a Software-as-a-Service (SaaS) system that seamlessly integrates with enterprise platforms to enhance MLR efficiency. Purpose-built for pharmaceutical and medical device companies, the software helps MLR reviewers efficiently assess and mitigate compliance risks and reduce comments and re-reviews.

SecureCHEK AI leverages a full hybrid AI model—the gold standard architecture for accuracy and hallucination control to ensure confidence and trust in the findings. Rapid deployment and the user-friendly interface minimize the learning curve, making it easy to get started.